Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New trial designs and potential therapies for pulmonary artery hypertension.
Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. Gomberg-Maitland M, et al. Among authors: rainisio m. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D82-91. doi: 10.1016/j.jacc.2013.10.026. J Am Coll Cardiol. 2013. PMID: 24355645 Free PMC article. Review.
Clinical trial design and new therapies for pulmonary arterial hypertension.
Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Sitbon O, et al. Among authors: rainisio m. Eur Respir J. 2019 Jan 24;53(1):1801908. doi: 10.1183/13993003.01908-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545975 Free PMC article. Review.
[New trial designs and potential therapies for pulmonary artery hypertension].
Gomberg-Maitland M, Bull TM, Saggar R, Barst RJ, Elgazayerly A, Fleming TR, Grimminger F, Rainisio M, Stewart DJ, Stockbridge N, Ventura C, Ghofrani AH, Rubin LJ. Gomberg-Maitland M, et al. Among authors: rainisio m. Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:106-18. Turk Kardiyol Dern Ars. 2014. PMID: 25697038 Turkish.
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, Kurzyna M, Nagueh SF, Barst R, Channick R, Dujardin K, Kronenberg A, Leconte I, Rainisio M, Rubin L. Galiè N, et al. Among authors: rainisio m. J Am Coll Cardiol. 2003 Apr 16;41(8):1380-6. doi: 10.1016/s0735-1097(03)00121-9. J Am Coll Cardiol. 2003. PMID: 12706935 Free article. Clinical Trial.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G. Sitbon O, et al. Among authors: rainisio m. Thorax. 2005 Dec;60(12):1025-30. doi: 10.1136/thx.2005.040618. Epub 2005 Jul 29. Thorax. 2005. PMID: 16055621 Free PMC article.
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Kaluski E, et al. Among authors: rainisio m. Cardiology. 2008;109(4):273-80. doi: 10.1159/000107791. Epub 2007 Sep 17. Cardiology. 2008. PMID: 17873492 Clinical Trial.
37 results